Filing Flows › Collegium Pharmaceutical (COLL) › Q3 2026 › vs Q3 2025
Collegium Pharmaceutical (COLL) Q3 2026 vs Q3 2025 (year over year)
Collegium Pharmaceutical's revenue rose $7.0M (+3%) from $209M in Q3 2025 to $216M in Q3 2026. The biggest changes: Azstarys +$26.5M (—); Nucynta IR −$15.3M (-48%); Nucynta ER −$12.9M (-57%). Gross margin 58.0% against 61.7% (-3.7 pts).
Collegium Pharmaceutical, Q3 2026: revenue $216M (+3% year over year), operating margin 13.3%, net earnings $21.8M, operating cash flow $86.5M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 58.0% | 61.7% | -3.7 pts |
| Operating margin | 13.3% | 29.7% | -16.4 pts |
| Net margin | 10.1% | 15.0% | -5.0 pts |
| Free cash flow margin | 39.9% | 37.4% | +2.5 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Belbuca | $57.7M | $58.3M | −$535K | -0.9% |
| Jornay PM | $51.9M | $41.8M | $10.1M | +24% |
| Xtampza ER | $45.8M | $50.5M | −$4.7M | -9% |
| Azstarys | $26.5M | $0 | $26.5M | — |
| Nucynta IR | $16.7M | $32.0M | −$15.3M | -48% |
| Nucynta ER | $9.9M | $22.8M | −$12.9M | -57% |
| Nucynta ER AG | $3.9M | $0 | $3.9M | — |
| Symproic | $3.6M | $4.0M | −$401K | -10% |
| Revenue | $216M | $209M | $7.0M | +3% |
| Gross profit | $125M | $129M | −$3.8M | -3% |
| Cost of revenue | $90.9M | $80.2M | $10.7M | +13% |
| Operating profit | $28.7M | $62.1M | −$33.4M | -54% |
| Operating expenses | $96.7M | $67.1M | $29.6M | +44% |
| Pre-tax earnings | $7.9M | $43.4M | −$35.5M | -82% |
| Other expense, net | $20.8M | $18.7M | $2.2M | +12% |
| Income tax benefit | $13.9M | −$11.9M | $25.8M | — |
| Net earnings | $21.8M | $31.5M | −$9.7M | -31% |
| Depreciation & amortization | $55.8M | $56.5M | −$669K | -1% |
| Share-based compensation | $12.4M | $9.8M | $2.6M | +27% |
| Working capital & other | $3.5M | $19.4M | −$15.9M | -82% |
| Operating cash flow | $86.5M | $78.4M | $8.1M | +10% |
| Free cash flow (OCF − capex) | $86.3M | $78.2M | $8.0M | +10% |
| Capital expenditures | $277K | $188K | $89K | +47% |
Questions
How much did Collegium Pharmaceutical's revenue grow year over year in Q3 2026?
Collegium Pharmaceutical's revenue rose $7.0M (+3%) from $209M in Q3 2025 to $216M in Q3 2026.
What drove Collegium Pharmaceutical's revenue change in Q3 2026?
Azstarys +$26.5M (—); Nucynta IR −$15.3M (-48%); Nucynta ER −$12.9M (-57%).